KalVista Pharmaceuticals
Dec 16, 2024 · KalVista is advancing science to empower everyday lives with innovative oral medicines. KalVista’s mission begins with hereditary angioedema, HAE. Patients & Caregivers
About Us - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system.
Pipeline - KalVista Pharmaceuticals
KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, beginning with hereditary angioedema (HAE).
KalVista Announces Orphan Drug Designation and NDA …
2 days ago · CAMBRIDGE, Mass. & SALISBURY, England, January 21, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted ...
KalVista Announces Orphan Drug Designation and NDA
2 days ago · KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant ...
KalVista Pharmaceuticals, Inc. (KALV) - Yahoo Finance
Find the latest KalVista Pharmaceuticals, Inc. (KALV) stock quote, history, news and other vital information to help you with your stock trading and investing.
KalVista Pharmaceuticals, Inc. (KALV) - Stock Analysis
5 days ago · Get a real-time KalVista Pharmaceuticals, Inc. (KALV) stock price quote with breaking news, financials, statistics, charts and more.
KalVista Announces FDA Acceptance of New Drug Application for ...
Sep 3, 2024 · KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for sebetralstat has been accepted by the FDA with a PDUFA goal date of June 17, 2025 .
News Releases - KalVista Pharmaceuticals
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 8, 2025-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to ...
KALV Stock Price | KalVista Pharmaceuticals Inc. Stock Quote …
6 days ago · KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases...
- Some results have been removed